-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Upgrades Cytokinetics to Buy, Raises Price Target to $95

Benzinga·12/19/2025 16:49:26
Listen to the news
Goldman Sachs analyst Paul Choi upgrades Cytokinetics (NASDAQ:CYTK) from Neutral to Buy and raises the price target from $55 to $95.